Search research articles
Contact Us
Filters
Showing results (91-100 of 95) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 95 results.
Gut
|
May 19, 2019
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab
Anthony Dohan, Benoit Gallix, Boris Guiu, et al.
Journal of Gastrointestinal Oncology
|
May 18, 2023
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma
David Piquemal, Roman Bruno, Barbara Bournet, et al.
The Lancet. Oncology
|
March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study
Stefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
Lancet (London, England)
|
June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2025
Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer
Alice Talpin, Ana Maia, Jean-Marie Carpier, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 95) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 95 results.
Gut
|
May 19, 2019
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab
Anthony Dohan, Benoit Gallix, Boris Guiu, et al.
Journal of Gastrointestinal Oncology
|
May 18, 2023
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma
David Piquemal, Roman Bruno, Barbara Bournet, et al.
The Lancet. Oncology
|
March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study
Stefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
Lancet (London, England)
|
June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2025
Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer
Alice Talpin, Ana Maia, Jean-Marie Carpier, et al.
Page
of 10